Na nso nso a, Shanghai Epiprobe Biotechnology Co., Ltd. (na-ezo dị ka "Epiprobe") mara ọkwa na ọ dechara fọrọ nke nta RMB 100 nde na Series B ego, nke a na-jikọtara nyekwara site ulo oru isi obodo, ọchịchị ulo oru mbo nyiwe na depụtara ụlọ ọrụ Yiyi Shares (SZ). : 001206).
Tọrọ ntọala na 2018, Epiprobe, dị ka onye nkwado na onye ọsụ ụzọ nke nleba anya pan-cancer n'oge, bụ ụlọ ọrụ teknụzụ dị elu na-elekwasị anya na nyocha mkpụrụ ndụ kansa na ụlọ ọrụ ọgwụ ziri ezi.N'ịwulite n'elu otu ndị ọkachamara epigenetics na nnukwu mkpokọta agụmakwụkwọ, Epiprobe na-enyocha ngalaba nke nchọpụta ọrịa cancer, na-akwado ọhụụ nke "idebe onye ọ bụla pụọ na ọrịa cancer," na-agba mbọ ịchọpụta mmalite, nchọpụta mmalite na ọgwụgwọ ọrịa cancer n'oge, si otú ahụ na-eme ka ndụ dịkwuo mma. Ọnụọgụ ndị ọrịa kansa iji kwalite ahụike nke ndị mmadụ niile.
Mgbe ha gwuchara afọ 20, ndị otu Epiprobe n'onwe ha chọtara usoro ọrịa kansa Aligned General Methylated Epiprobes (TAGMe), bụ nke zuru ụwa ọnụ na ọrịa cancer dị iche iche, wee si otú a gbasaa ngwa ngwa.
N'ihe gbasara teknụzụ nchọpụta, a na-ewere pyrosequencing dị ka "ọkọlọtọ ọla edo" maka nchọpụta methylation, nke na-adabere na ntughari bisulfite, ma na-egosipụta adịghị ike dị ka arụmọrụ ngbanwe na-akwụghị ụgwọ, nbibi DNA dị mfe, ihe dị elu chọrọ maka ndị na-arụ ọrụ, na ịdabere na ngwá ọrụ bara uru.Ụkọ ndị a na-egbochi ngwa ya.Epiprobe, site n'ịme ọganihu teknụzụ, n'onwe ya ewepụtala teknụzụ nchọpụta methylation ọhụrụ - Me-qPCR na-enweghị ọgwụgwọ bisulfite, nke na-ebelata ọnụ ahịa ma melite nkwụsi ike nchọpụta na ịrụ ọrụ ụlọ ọgwụ, na-eme ka nchọpụta ahụ dị mfe ma dị mfe.
Epiprobe, na-adabere na isi ụlọ ọrụ pan-cancer markers na ụzọ nchọpụta methylation, etinyela ihe karịrị 50 patent ụlọ na mba ụwa, ma nweta ikike iji guzobe onye na-akwado patent siri ike.
Ugbu a, Epiprobe na-arụkọ ọrụ ọnụ na n'elu 40 n'elu ụlọ ọgwụ na China, gụnyere Zhongshan Hospital, International Peace Maternity na Child Health Hospital, na Changhai Hospital wdg, na emejuputa atumatu nnukwu ngwaahịa nhazi na ndị inyom na-amụ nwa ọrịa cancer (gụnyere cervical cancer, endometrial cancer) , ọrịa kansa urothelial (gụnyere kansa eriri afọ, ọrịa urethra, ọrịa kansa pelvis), kansa akpa ume, kansa thyroid, kansa hematological na ọrịa cancer ndị ọzọ.Emejuputala nkwado nke kpuru okpukpu abụọ n'ime ihe nlele ụlọ ọgwụ 70,000 nwere ngụkọta nke ụdị ọrịa kansa 25.
N'ime ngwaahịa ndị a, maka ngwaahịa nchọpụta ọrịa kansa ịmụ nwa, etinyere nkwado nke kpuru okpukpu abụọ n'ihe karịrị ihe nlele ụlọ ọgwụ 40,000, na ebipụtala usoro nyocha n'akwụkwọ akụkọ agụmakwụkwọ ama ama na mba ụwa dịka Nnyocha Ọrịa Cancer, Clinical na Medicine Translational, na A na-emejuputa atumatu ụlọ ọgwụ dị iche iche buru ibu.Ka R&D na-aga n'ihu na akụrụngwa na-abawanye mgbe niile, pipeline ngwaahịa ụlọ ọrụ na-abawanye nwayọ nwayọ.
Nwada Hua Lin, onye isi oche nke Epiprobe kwuru na: “Ọ bụ nnukwu ihe ùgwù anyị ịbụ ndị isi ụlọ ọrụ mmepụta ihe mara mma ghọtara na ịkwado ya.Ihe e ji mara Epiprobe bụ nnukwu mkpokọta agụmakwụkwọ ya, teknụzụ pụrụ iche, yana nyocha ụlọ ọgwụ siri ike, nke nwetagoro ntụkwasị obi nke ọtụtụ nnọkọ.N'ime afọ anọ gara aga, otu na ọrụ ụlọ ọrụ na-abawanyewanye nke ọma.N'ụbọchị ndị na-abịa, anyị agaghị agbanahụ mbọ ọ bụla iji kpọọ ndị mmekọ nwere mmasị ka ha na-arụkọ ọrụ na ịrụkọ ọrụ ọnụ, si otú a na-akwalite R&D mgbe niile na usoro ndebanye aha, yana inye ndị ụlọ ọgwụ na ndị ọrịa ọrụ nyocha ọrịa kansa kacha mma. ngwaahịa."
Oge nzipu: Eprel-11-2022